These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 16169728)

  • 21. Adjuvant endocrine therapy in postmenopausal breast cancer.
    Ingle JN
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):480S-5S. PubMed ID: 12538504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in adjuvant endocrine therapy for postmenopausal women.
    Lin NU; Winer EP
    J Clin Oncol; 2008 Feb; 26(5):798-805. PubMed ID: 18258989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
    Ingle JN
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1031s-1036s. PubMed ID: 16467121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
    Wheler J; Johnson M; Seidman A
    Semin Oncol; 2006 Dec; 33(6):672-80. PubMed ID: 17145347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer.
    Koeberle D; Thuerlimann B
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):5-10. PubMed ID: 16375638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.
    Spicer J; Ellis P
    Cancer Lett; 2007 Apr; 248(2):165-74. PubMed ID: 16919870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The evolving role of endocrine therapy for breast cancer].
    Jinno H; Ikeda T; Takayama S; Kitajima M
    Nihon Rinsho; 2006 Mar; 64(3):547-54. PubMed ID: 16529048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The evolving role of letrozole in the adjuvant setting: first results from the large, phase III, randomized trial BIG 1-98.
    Monnier A
    Breast; 2006 Feb; 15 Suppl 1():S21-9. PubMed ID: 16500237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting.
    Bhatnagar AS
    Breast; 2006 Feb; 15 Suppl 1():S3-13. PubMed ID: 16500235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
    Singh Ranger G
    J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
    Fallowfield L; Cella D; Cuzick J; Francis S; Locker G; Howell A
    J Clin Oncol; 2004 Nov; 22(21):4261-71. PubMed ID: 15514369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Monnier AM
    Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
    Buzdar AU; Cuzick J
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
    Chlebowski RT
    Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():25-34. PubMed ID: 19101792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aromatase inhibitors for the treatment and prevention of breast cancer.
    Kalidas M; Brown P
    Clin Breast Cancer; 2005 Apr; 6(1):27-37. PubMed ID: 15899070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK; Nielsen DL; Lindberg H; Kamby C
    Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant endocrine therapies for postmenopausal women with early breast cancer: standards and not.
    Dellapasqua S; Castiglione-Gertsch M
    Breast; 2005 Dec; 14(6):555-63. PubMed ID: 16188442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program.
    Aapro M
    Breast; 2006 Feb; 15 Suppl 1():S30-40. PubMed ID: 16500238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.